Philina Lee is CCO at Blueprint Medicines Corp (BPMC). They have made 5 open-market trades across 1 company since 2023, most recently 2025-07-17.
CIK 0001845080
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| BPMC | 63,349 | $8.2M |
Shares reported on the most recent Form 4, priced at the 2025-07-21 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BPMC | SELL | 2025-03-05 | 2025-03-07 | $88.80 | $663K | +5.7% | -6.3% | +49.4% |
| BPMC | SELL | 2024-08-05 | 2024-08-07 | $93.19 | $7.8M | +4.7% | -5.4% | +6.8% |
| BPMC | SELL | 2024-03-13 | 2024-03-15 | $90.47 | $1.3M | +4.3% | -6.3% | +17.1% |
| BPMC | SELL | 2024-03-07 | 2024-03-11 | $90.69 | $532K | +1.0% | +1.5% | +16.7% |
| BPMC | SELL | 2023-03-06 | 2023-03-08 | $45.70 | $151K | +3.2% | -3.4% | +32.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.